UNSPSC 51401801: Ciclotizolam

This classification denotes a benzodiazepine with the molecular formula C20H18BrClN4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JK517QTN4Q, chemically known as 2-bromo-4-(o-chlorophenyl)-9-cyclohexyl-6h-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine but generally known as ciclotizolam, which bears US NIH Compound Identifier 71949. European Medicines Agency schedules Ciclotizolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06251MIG.

UNSPSC 51401801 Ciclotizolam is a Commodity code that nominally covers a specific pharmaceutical agent, but recent state and local procurement activity under this code shows little alignment with the pharmaceutical category itself. The three recent opportunities posted under this code — a Seminole County naloxone and drug deactivation system procurement, a Texas HHS Request for Information on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products — reflect broader pharmaceutical supply, pharmacy benefit management, and emergency response product sourcing rather than the ciclotizolam compound the code nominally describes. The issuing bodies represent a mix of county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and state cooperative purchasing consortia serving multiple jurisdictions (MMCAP, administered by Minnesota Department of Administration). This fragmentation suggests the code is being used as a catch-all for pharmaceutical procurement across heterogeneous state and local entities rather than as a precise product classifier.

Recent activity spans Florida, Texas, and Minnesota, with the MMCAP opportunity extending to Oregon through its multistate cooperative structure. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the deadline date appears inconsistent with the posting date, suggesting a data quality issue in the source). Texas HHS issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs prior to formal RFP issuance. MMCAP issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers. The code shows modest recent activity, but the mismatch between the nominal pharmaceutical compound and the actual procurements (emergency response products, PBM alternatives, and generic bulk supply) indicates vendors should verify code alignment with specific opportunities rather than rely on the UNSPSC category name alone.